Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

Latest from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins


PD-1 Inhibition Requires Further Refinement in Melanoma

February 25, 2015

In an interview with OncLive, Suzanne L. Topalian, MD, director of the Melanoma Program at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discussed the rapid advance of nivolumab and potential next-steps.

Dr. Brahmer on Immunotherapy Development in Lung Cancer

February 17, 2015

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses immunotherapy and how it can advance as a treatment option for patients with lung cancer.

Dr. Topalian on Biomarkers for Anti- PD-1 Therapies in Melanoma

February 12, 2015

Suzanne Topalian, MD, professor of surgery and oncology, John Hopkins Medicine, and director of the melanoma program, Sidney Kimmel Comprehensive Cancer Center, compares biomarker detection for anti- PD-1 therapies like nivolumab to anti-CTLA-4 therapies like ipilimumab for the treatment of melanoma.

Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins Medicine Joins OncLive in Strategic Alliance Partnership Program

January 28, 2015

OncLive® and the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins Medicine have become collaborators to raise awareness of leading innovations in cancer care through OncLive's Strategic Alliance Partnership program, OncLive announced.

Brahmer Expects Rapid Approval for First PD-1 Inhibitor in Lung Cancer

January 25, 2015

Immune checkpoint inhibitors targeted against PD-1 and its ligand PD-L1 have rapidly advanced as treatments for patients with melanoma and non–small cell lung cancer (NSCLC), following their initial debut in 2012.

ODAC Unanimously Supports Approval of First Biosimilar

January 07, 2015

In a 14-0 vote, the FDA's ODAC unanimously recommended approval of EP2006, a biosimilar version of filgrastim. If the FDA follows the recommendation, the drug would become the first biosimilar approved in the United States.

ODAC Votes Against Panobinostat in Multiple Myeloma

November 06, 2014

In what was described as a very difficult decision, ODAC voted 5-2 against the accelerated approval of the HDAC inhibitor panobinostat in combination with bortezomib and dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.

Hopkins Researcher Discusses AR-V7 and Resistance to AR-Targeting Agents

October 04, 2014

Androgen receptor splice variant-7 (AR-V7) is a truncated form of the AR that does not have the ligand-binding domain. Detection of AR-V7 in circulating tumor cells (CTCs) can be used to predict resistance to AR-targeting agents, such as abiraterone or enzalutamide.

Sipuleucel-T Helps ADT Boost Prostate Cancer Immunity

August 28, 2014

Sipuleucel-T (Provenge) is effective when given either before or after androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer (BRPC) who face a high risk of developing metastases, a study has found.

Anti-PD-L1 Antibody MEDI4736 Shows Clinical Activity in NSCLC and Is Well Tolerated

July 30, 2014

The anti-PD-L1 antibody MEDI4736 has early and durable activity in patients with non–small cell lung cancer (NSCLC) of both squamous and nonsquamous histology, with higher objective response rates occurring in PD-L1–positive patients, according to results of an ongoing phase I study.

Blood Test Predicts Resistance to Enzalutamide in mCRPC

June 23, 2014

It may be possible to predict which men with metastatic castration-resistant prostate cancer will not respond to enzalutamide by using a simple blood test to detect the presence of AR-V7 in circulating tumor cells.

Reducing the Costs of Cancer Might Involve 'Physician Heal Thyself'

February 14, 2014

To reduce the costs of cancer, community oncologists increase the use of evidence-based treatments, standardize care with pathways, transition away from fee-for-service, and change communication with patients about reasonable end-of-life care.

Dr. Levis on the Ideal Use of Quizartinib in FLT3-ITD AML

February 05, 2014

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).

Specific Gene Alterations Explain Survival Disparities in HNSCC

December 20, 2013

Alterations in specific genes involved in the formation of tissues and organs during embryonic development could be responsible for survival disparities seen between African-American and non-Latino white men with head and neck cancer.

Predicting Risk of Aggressive Prostate Cancer Through Biomarkers in Blood

December 16, 2013

A new study has shown a possible correlation between men with short-ended chromosomes in the immune cells of their blood and an increased risk of developing aggressive prostate cancer, potentially pointing the way toward an accessible biomarker that could help inform treatment and surveillance decisions.

x